SHAREHOLDERS ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors Inotiv, Inc. - NOTV - Stock News Source

MIAMI FLORIDA / ACCESS CABLE / July 26, 2022 / Regenerative Medicine Organicell, Inc.. (OTCQB:OCEL), a clinical-stage biopharmaceutical company primarily focused on developing innovative biologic therapies in the extracellular vesicle space, today announced that the Board of Directors has appointed Matt Sinnreich as Chief Operating Officer and Interim Chief Executive Officer. Sinnreich will replace Mr. Albert Mitrani, Founder of Organell and CEO since September 2019, who will step down to serve as Executive Vice President of Sales for the company.

Sinnreich, an early-stage investor in Organell, helped finance the company’s 2020 audit to update its financials and was instrumental in creating its flagship brand: Zofin.

Sponsored Content:

Sinnreich comes from a business and development background. His track record includes profitable corporate exits, successful real estate transactions, and owner-operated residential and commercial real estate developments. Sinnreich has closed tens of millions in various financial instruments including everything from traditional real estate debt, private company fundraising, to secured derivatives and swaps.

Sinnreich is an early-stage investor in ready-to-drink tequila-seltzer Mamitas and owns a minority stake in Craig’s Vegan Ice Cream.

Sinnreich graduated from the University of Miami School of Business in 2008, where he also won the 2008 Rothschild Business Plan Competition.

In response to his appointment, Sinnreich stated:

Sponsored Content: is a veteran-owned e-commerce with over 40,000 items at great prices and always free shipping

“I am honored and grateful that the board and the new investment groups have entrusted me to take Organell to the next level. I believe that exosomes are a key element in the future of medicine and this company has the team to make it happen. Albert and Mari Mitrani are pioneers in this space. They assembled an amazing scientific team, developed an amazing product line, and built world-class production labs. All the ingredients are here for this company to become a great success.

As COO and acting CEO, I will focus on creating additional funding vehicles, increasing awareness of our products and brand, and most importantly, maintaining an honest and transparent relationship with shareholders.

My priorities at the moment are to work with our CFO, Ian Bothwell, to develop the core executive team at Organell. I will leverage my network to surround myself with the best and brightest in the medical and financial fields. I plan to create a robust ERP and data management system and establish additional funding vehicles to fund our clinical trials.

I will also be bringing Organicell’s newest biologic to market: Patient Pure X™ (PPX™).

PPX™ is Organicell’s first autologous product that is an unengineered biologic that concentrates a patient’s exosomes from their own peripheral blood. In plain language: we can concentrate a patient’s exosomes from her own blood.

The scientific team and researchers at Organell are currently conducting studies to test the efficacy of PPX on pain, hair loss, its potential for aesthetic uses, and surgical recovery.

Organell’s products have shown promising results in the initial data that has been collected. Once the company has adequate data from our clinical trials to make the claims we are studying, I believe this company will be a disruptor in the biotech industry.”

About Organell Regenerative Medicines, Inc.

Organicell Regenerative Medicine, Inc. (OTCQB:OCEL) is a clinical-stage biopharmaceutical company primarily focused on the development of innovative biological therapies for the treatment of degenerative diseases and the provision of other related services. The Company’s proprietary products are derived from perinatal sources and are manufactured to retain exosomes, hyaluronic acid, and natural proteins without the addition or combination of any other substances or diluents. For more information, visit

Forward-looking statements

Some of the statements contained in this Press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as “will,” “believes,” “expects,” “potential,” or similar expressions, which involve known risks and uncertainties and unknown. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they involve assumptions, risks and uncertainties, and these expectations may turn out to be incorrect. We remind you that actual results could vary materially as a result of known and unknown risks and uncertainties, including, but not limited to: potential issues related to our financial condition, competence, ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, the success of clinical programs, the ability to retain key customers, our failure to expand sales and distribution channels, laws or regulations affecting our operations, including the price of products, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally, and other known and unknown risks and uncertainties, including risk factors discussed in the Company’s periodic reports that are filed with the SEC and are available on the s SEC website ( ). You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this Press release may change over time and may or may not be accurate after the date of publication. Organell does not intend and specifically disclaims any obligation to update the information in this press release.

Media Contact:
Joshua Rodriguez
CEO and Founder
CNA Finance, LLC.
(503) 464-6502

FONT: Regenerative Medicine Organicell, Inc.

See source version at access

Source link

Leave a Reply

Your email address will not be published.